28.04.2012

Sanofi Strong in Emerging Markets as Rivals Flag

French drugmaker Sanofi posted better-than-expected quarterly results, bolstered by strong emerging markets, breaking with a trend of earnings misses by European rivals AstraZeneca and GlaxoSmithkline. Sanofi performed strongly in China, Brazil and Russia - crucial areas for international drugmakers as sales in their home markets decline due to patent expiries and government cuts in healthcare spending. more03.11.2011

Global Pharma to Pump Cash Into Russia

  Viiv Healthcare, a GlaxoSmithKline and Pfizer joint venture, will start manufacturing HIV medicines in Russia in partnership with local drugmaker Binnopharm. Agreeing a local partnership is a way for international drug companies to secure guaranteed sales in Russia, which wants to reduce dependence on imported drugs. Global drugmakers have pledged at least $1 billion in investments in Russian manufacturing, packaging and research and development. more28.07.2011

Sanofi-Aventis Q2 Profit Slips

Sanofi-Aventis reported a 13.2% decline in its second-quarter business net income to €2.15 billion  from €2.48 billion last year. Business earnings per share were €1.64, down 13.7% from €1.90 in the 2010 second quarter. At constant exchange rates, business earnings per share decreased by 7.4%. more14.06.2011

E&Y Sees $1-5 Billion As Sweet Spot For Biotech M&A

Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough environment, Ernst & Young said.        more11.04.2011

Sanofi Completes Genzyme Takeover

Sanofi-Aventis said it has completed its takeover of U.S. biotechnology company Genzyme. The companies agreed in February on a deal worth about $20.1 billion. The acquisition gives Sanofi access to Genzyme's business in treating rare diseases and is expected to help the company combat sales erosion from drugs facing cheap generic competition. more04.04.2011

Sanofi Says Gains Control Of Genzyme

French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its growth areas. more30.03.2011

Sanofi CVRs Tied To Genzyme May Start Trading April 4

Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its tender offer. The French drugmaker said on Tuesday that the U.S. Securities and Exchange Commission (SEC) had cleared the trading of contingent value rights (CVR) under the ticker. more18.03.2011

Genzyme Says In Talks To Bring R&D To Russia

U.S. biotech company Genzyme said on Thursday it planned joint research projects with Russian high-tech centre ChemRar, joining a growing number of global drugmakers seeking to gain a local presence. Establishing a presence is a way for international drug companies to secure guaranteed sales in Russia, which wants to reduce dependence on imported drugs. more08.03.2011

Henri Termeer To Leave Genzyme With About $160 Million

Genzyme Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final - and stands to earn considerably more should Genzyme's multiple sclerosis drug prove as successful as Termeer has predicted. Termeer is set to receive compensation of $145.9 million from his Genzyme shares, stock options and restricted stock units on completion of the $20.1 billion deal with Sanofi , according to a regulatory filing. more17.02.2011

French Drugmaker Sanofi-Aventis SA Reaches Finall Agreement to Buy Genzyme Corp

French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group's drugs, the companies said on Wednesday. more